Sign In
Buy LYRA
$0.495
+0 (+0%)
At Close: Jun 03, 2026
WATERTOWN, Mass., April 17, 2026 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (the "Company") today announced its intention to voluntarily file a Form 25 Notification of Delisting with the U.S. Securit
Gold Rises Sharply; Lyra Therapeutics Shares Plunge
12:26pm, Monday, 12'th Jan 2026
U.S. stocks traded mixed midway through trading, with the Nasdaq Composite gaining more than 50 points on Monday.
Lyra Therapeutics Provides Corporate Update
07:00am, Monday, 12'th Jan 2026
WATERTOWN, Mass., Jan. 12, 2026 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA) (“Lyra” or the “Company”) today announced that its Board of Directors has decided to suspend further
Lyra Therapeutics (NASDAQ:LYRA) Trading Up 0.3% – Time to Buy?
01:47am, Saturday, 27'th Dec 2025
Lyra Therapeutics, Inc. (NASDAQ: LYRA - Get Free Report)'s share price was up 0.3% on Friday. The stock traded as high as $3.70 and last traded at $3.59. Approximately 32,339 shares changed hands duri
Lyra Therapeutics (NASDAQ:LYRA) Trading Up 4.5% – Should You Buy?
01:50am, Thursday, 04'th Dec 2025
Lyra Therapeutics, Inc. (NASDAQ: LYRA - Get Free Report)'s share price was up 4.5% on Wednesday. The stock traded as high as $4.32 and last traded at $4.19. Approximately 48,758 shares traded hands du
Lyra Therapeutics, Inc. (LYRA) Reports Q3 Loss, Lags Revenue Estimates
06:15pm, Wednesday, 12'th Nov 2025
Lyra Therapeutics, Inc. (LYRA) came out with a quarterly loss of $3.38 per share versus the Zacks Consensus Estimate of a loss of $5.98. This compares to a loss of $9 per share a year ago.
Lyra Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update
04:01pm, Wednesday, 12'th Nov 2025
– Company plans new, confirmatory Phase 3 clinical trial of LYR-210 for treatment of chronic rhinosinusitis (CRS) without nasal polyps, on path to NDA submission –
Lyra Therapeutics Announces Clinical Plan for LYR-210 and Late-Breaking Oral Presentation of Phase 3 ENLIGHTEN 2 Study
07:00am, Monday, 06'th Oct 2025
Company outlines clinical plan for LYR-210 based on FDA meeting on the path to NDA submission Positive ENLIGHTEN 2 results highlighted at the AAO-HNS 2025 Annual Meeting WATERTOWN, Mass., Oct. 06, 2
Lyra Therapeutics, Inc. (LYRA) Reports Q2 Loss, Beats Revenue Estimates
06:16pm, Tuesday, 12'th Aug 2025
Lyra Therapeutics, Inc. (LYRA) came out with a quarterly loss of $5.51 per share versus the Zacks Consensus Estimate of a loss of $5.79. This compares to a loss of $14.5 per share a year ago.
Lyra Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update
04:01pm, Tuesday, 12'th Aug 2025
– Positive ENLIGHTEN 2 Phase 3 results announced in June 2025 propel business activities in manufacturing, regulatory strategy and ENLIGHTEN clinical dataset analysis to advance path forward for LYR
Upfront Gross Proceeds of $5.0 Million, with Up to Approximately $9.8 Million of Additional Gross Proceeds Assuming the Cash Exercise in Full of Private Placement Warrants Upfront Gross Proceeds of $5
Lyra Therapeutics: Regulatory Pathway For Non-Polyp Patients, An Underappreciated Catalyst
04:14pm, Monday, 16'th Jun 2025
Lyra Therapeutics has lost >90% of its value since announcing the failed ENLIGHTEN-1 trial, despite the recent announcement of a clearly positive ENLIGHTEN-2. Considering a clearly positive phase 3, s
Lyra Therapeutics (LYRA) Upgraded to Buy: Here's Why
01:01pm, Thursday, 12'th Jun 2025
Lyra Therapeutics (LYRA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Lyra Stock Soars 356% in a Week on Strong Rhinosinusitis Study Success
01:56pm, Thursday, 05'th Jun 2025
LYRA skyrockets 356% after its lead nasal implant, LYR-210, meets key goals in a pivotal phase III chronic rhinosinusitis study.
This penny stock just spiked 550% in a day; Time to buy?
09:40am, Monday, 02'nd Jun 2025
Lyra Therapeutics (NASDAQ: LYRA) ‘s shares surged 550% in pre-market trading on Monday following a breakthrough in its drug trials.
